Convergent Dental, a privately held dental device company, announced that Solea, the first FDA cleared CO2 9.3 micron dental laser for hard and soft tissue, has also been cleared to perform osseous tissue procedures.

With this expanded indication, Solea can be used to treat not only cavity preparations and soft tissue surgery, but also bone cutting, shaving, re-contouring and resection. Convergent Dental will be showcasing Solea at ADA 2015 in Washington, D.C. from November 5-10, 2015.

Solea’s osseous tissue clearance allows dentists to perform procedures ablating bone with speed, precision and less bleeding. As a result, patients may experience less post-operative discomfort and faster healing times. These benefits improve the patient experience, reduce chair time and increase the economic impact for a dental practice.

"Convergent Dental’s rapidly expanding clinical indications for Solea is another example of their commitment to innovation," said Dr. Simon Bernstein.

"With this new osseous tissue clearance by the FDA, Solea’s unique 9.3 micron wavelength continues to create the opportunity for minimally invasive dentistry."

"This osseous tissue clearance is a critical component of our long term grow strategy. It adds even greater value for our current customers who can add more procedures to their repertoire and makes Solea a compelling option for specialists including periodontists and oral surgeons," said Convergent Dental CEO Michael Cataldo.

Convergent Dental’s focus on continuous innovation has made it the fastest growing all-tissue dental laser company in the United States.